Spinal Muscular Atrophy News and Research

RSS
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.
New cell type could play an important role in spinal cord injury and disease

New cell type could play an important role in spinal cord injury and disease

Walgreens, MDA team up to offer free seasonal flu shots

Walgreens, MDA team up to offer free seasonal flu shots

WSU researcher receives $418,000 NINDS grant to study spinal muscular atrophy

WSU researcher receives $418,000 NINDS grant to study spinal muscular atrophy

Two ALS-associated genes work in tandem to support long-term survival of motor neurons

Two ALS-associated genes work in tandem to support long-term survival of motor neurons

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

MDA announces $13.7M in grants to 40 new muscular dystrophy research initiatives

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

NIH/NINDS awards AMRI to develop pre-clinical drug candidate for spinal muscular atrophy

Repligen first quarter total revenue increases 9% to $7,654,000

Repligen first quarter total revenue increases 9% to $7,654,000

New hope for infants born with Spinal Muscular Atrophy

New hope for infants born with Spinal Muscular Atrophy

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

New research on spinal muscular atrophy

New research on spinal muscular atrophy

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Caliper first quarter revenue increases 25% to $35.8 million

Caliper first quarter revenue increases 25% to $35.8 million

FightSMA to host panel discussions on spinal muscular atrophy

FightSMA to host panel discussions on spinal muscular atrophy

Repligen anticipates 30% increase in total revenues for 2011

Repligen anticipates 30% increase in total revenues for 2011

Quest Diagnostics completes Athena Diagnostics acquisition

Quest Diagnostics completes Athena Diagnostics acquisition

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Life Sciences introduces ELISA system to detect SMN protein

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Scientists discover new way to generate human motor nerve cells

Scientists discover new way to generate human motor nerve cells